Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | METTL3 | Q86U44 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27598109 | 0.83 | KDM4E (0.58) | NPC1RAB9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL1500340 | 0.81 | RAB9A (0.51) | NPC1RAB9ARXFP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10513008 | 0.80 | PIK3CG (0.50) | NPC1RAB9ARXFP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22527827 | 0.80 | TSHR (0.53) | NPC1RAB9AALDH1A1TSHRMETTL3 | |
| SCHEMBL12419636 | 0.78 | TSHR (0.68) | NPC1RAB9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL4822612 | 0.78 | KDM4E (0.47) | NPC1RAB9ARXFP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL23018101 | 0.77 | RXFP1 (0.38) | NPC1RAB9ARXFP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL23633192 | 0.76 | ALDH1A1 (0.56) | NPC1RAB9ARXFP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1500225 | 0.76 | RXFP1 (0.45) | NPC1RAB9ARXFP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL19736961 | 0.75 | RXFP1 (0.55) | NPC1RAB9ARXFP1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472160-B1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-24 | — | — | EP | disclosed |
| US-10894793-B2 | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-19 | — | — | US | disclosed |
| US-20190169199-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-06 | — | — | US | disclosed |
| WO-2017216292-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894793-B2 | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors | PIK3CA, PIK3CD, PIK3CB | NPC1 3338/4885RAB9A 2009/4885RXFP1 4817/4885 |
| US-20190169199-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | NPC1 3338/4885RAB9A 2009/4885RXFP1 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.